The purpose of the present trial is therefore to assess effects of arginine vasopressin vs.
saline placebo on hospital admission rate (primary end point), as well as hemodynamic
variables, fluid resuscitation requirements and hospital discharge rate (secondary study end
points) in presumed traumatic hemorrhagic shock patients with a systolic arterial blood
pressure <90 mm Hg after 10 min of standard shock treatment. Accordingly, the study reflects
an add-on design to standard traumatic shock therapy.
The hypothesis is that both arginine vasopressin and saline placebo have comparable effects
on hemodynamic variables, fluid resuscitation requirements, and hospital admission and
discharge rate. The alternative hypothesis is that arginine vasopressin has more beneficial
effects on hemodynamic variables, fluid resuscitation requirements, and hospital admission
and discharge rate than saline placebo.